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Abstract
Background: Osteoarthritis is thought to be the most prevalent chronic and disabling joint disease in animals and
humans. At present, there is no ideal treatment option. The aim of this study was to assess the effects of the
treatment with oral diacerein on articular cartilage, synovial membrane and subchondral bone in an experimental
rabbit model of osteoarthritis by micro-CT evaluation and histological analysis. To this purpose, osteoarthritis was
surgically induced on one knee of 16 rabbits using the contralateral knee as healthy controls. Treatment was started
three weeks later and lasted eight weeks. Animals were divided into two groups for treatment: Placebo (treated
daily with oral saline) and diacerein (treated orally with 1.5 mg/kg/day of diacerein).
Results: Sample analysis revealed that this model induced osteoarthritis in the operated knee joint. Osteoarthritis
placebo group showed a significant increase in non-calcified cartilage thickness and volume with respect to the
control placebo group and important changes in the synovial membrane; whereas the parameters measured in
subchondral bone remained unchanged. In the osteoarthritis diacerein-treated group the results showed an
improvement with respect to the OA placebo group in all parameters, although the results were not statistically
significant.
Conclusion: The results of this animal study suggested that the diacerein treatment for OA may be able to ameliorate
the swelling and surface alterations of the cartilage and exert an anti-inflammatory effect on the synovial membrane,
which might contribute to OA improvement, as well as an anabolic effect on subchondral trabecular bone.
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Background
Osteoarthritis (OA) is a heterogeneous chronic disease
affecting all tissues of the synovial joint. It is now ac-
cepted that the disease etiology is multiple and involves
various mechanical, biochemical and genetic factors, as
well as molecular and enzymatic feedback loops. Osteo-
arthritic changes are primarily the result of a disturbance
in the remodelling processes of tissues resulting from
the failure of cells to maintain a homeostatic balance; as
the disease advances, the catabolic process exceeds the
anabolic ones leading to progressive joint tissue lesions.
The morphological changes observed in OA include a
variable degree of synovial inflammation, principally at
the clinical stage of the disease, which in turn produces
inflammatory mediators (inflammatory cytokines), which
play a pivotal role in the pathophysiological mechanisms
of the OA [1, 2].
The pharmacological treatment of OA includes differ-
ent types of drugs that can be classified on basis of their
mode of action. Current treatment options are focused
on pain relief and improvement of joint function, includ-
ing analgesics and non-steroidal anti-inflammatory
drugs; unfortunately, their use in chronic treatments has
been limited by the deleterious side effects on cartilage
[3] and gastrointestinal tract [4]. Recent studies have de-
scribed drugs with the ability of providing symptomatic
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relief by targeting the underlying pathology of OA, par-
ticularly in cartilage and subchondral bone, and with less
secondary effects; such agents have been classified as
symptomatic slow-acting drugs for OA (SYSADOAs)
which are expected to delay, stabilise or reverse the
pathological changes in OA joints, limiting the progres-
sion of the disease [5]. This group of drugs includes
diacerein, an anthraquinone derivative (4,5-diacetyloxy-
9,10-dioxo-anthracene-2-carboxylic acid), which is an
oral anti-inflammatory, analgesic and antipyretic agent
developed specifically for the treatment of OA.
It is actually well-known the contribution of pro-
inflammatory cytokines to cartilage degradation in OA
[6, 7] including interleukin-1 (IL-1) which stimulates the
degradation process of cartilage and suppresses cartilage
matrix synthesis. Rhein, the active metabolite of diacer-
ein, has shown in vitro and in vivo the inhibition of the
IL-1β, as well as the reduction of the collagenase pro-
duction by joint chondrocytes, the reduction of fibrino-
lytic activity in synovial fluid [8, 9] and the stimulation
of the production of cartilage growth factors [10]. This
way of action turned diacerein into an interesting option
for the treatment of OA without the side effects of
NSAIDs [11].
In a previous study in dogs [12], diacerein treatment sig-
nificantly reduced the severity of morphologic changes in
the knee joint compared to placebo, using the SFA
(Societé Française d’Arthroscopie) score and, in the
same study, the Mankin scores were lower for the dia-
cerein group. In another study in rats [13], the treat-
ment with diacerein produced the best functional results
represented by a greater joint extension. In addition, sev-
eral trials in humans suggested beneficial role of diacerein
in hip and knee OA with results similar to those obtained
by NSAIDs during the active treatment phase [14]. Bartels
et al. (2010) [15] described a small reduction of pain in
patients treated with diacerein during the first 6 months,
whereas Pavelka et al. (2007) [16] reported a statistical su-
periority of diacerein versus placebo in pain control and
tenderness of the joint; Singh et al. (2012) [17] reported
an additive effect with diclofenac for pain and improve-
ment of the joint motion.
The aim of this study was to test the effectiveness of the
treatment with oral diacerein in an experimental early
rabbit model of OA; histology and histomorphometry
techniques were used and the results were compared with
a new methodology to determine the cartilage and sub-
chondral bone structure, using micro-computed tomog-
raphy (micro-CT) without contrast techniques.
Methods
Pre- and postoperative care. Osteoarthritis induction
Sixteen adult female (6–7 months old, mean weight 5
Kg) healthy New Zealand white rabbits (Granja San
Bernardo, Navarra, Spain) were used, after approval of
the protocol by the Ethical Committee of the University
of Santiago de Compostela (Reference number: AE-LU-
002/09/FUN01/PAT.(06)E). All animals were subjected
to surgery and throughout the procedures they were
housed in cages at the Animal Research Facility, Univer-
sity of Santiago de Compostela, Lugo, Spain. The proce-
dures were performed according to local and European
regulations on care and use of research animals, and this
paper was written in accordance with the ARRIVE state-
ment [18]. The rabbits were monitored daily during the
entire experimental procedure by an accredited veterinar-
ian, trained in laboratory animal science.
The protocol used has been deeply described in a re-
cently published article [19]. Summarising, OA was in-
duced by anterior cruciate ligament transection (ACLT)
and partial medial meniscectomy of one knee (randomly
chosen) using the contralateral knee as untreated control.
Animals were anaesthetised using isoflurane (2.5–4 %,
Isova-vet, Schering-Plough, Madrid, Spain) after pre-
medication with a combination of medetomidine (50 μg/
Kg IM; Domtor, Esteve, Barcelona, Spain) and ketamine
(25 mg/Kg IM; Imalgène 1000, Merial, Toulouse, France).
Each animal received peri- and post-operative buprenor-
phine (1 mg/Kg IM; Buprex, RB Pharmaceuticals,
Berkshire, UK), antibiotic prophylaxis with enrofloxacin
for a week (15 mg/Kg SC once a day; Ganadexil 5 %,
Invesa, Barcelona, Spain) and meloxicam (20 μg/Kg SC;
Metacam, Boehringer Ingelheim España, Barcelona, Spain)
for three days after surgery.
Three weeks after surgery, eight animals were ran-
domly selected in each experimental group. The control
group was treated with 5 mL of saline (NaCl 0.9 %) and
the treatment group with 1.5 mg/Kg of diacerein. Both
treatments were administered daily and directly into the
mouth using a 5 ml syringe. The group distribution is
represented in Fig. 1.
Necropsy and preparation of histological specimens
Rabbits were sacrificed by sodium pentobarbital over-
dose (100 mg/Kg IV; Dolethal, Vétoquinol, France) after
sedation with ketamine (25 mg/Kg IM; Imalgène 1000,
Merial, Toulouse, France). A complete necropsy of all
the animals was performed to evaluate the presence of
any alterations other than those in knee joints. After dis-
secting the articulation, two cylinders of 2.9 mm diam-
eter and 8 mm length were obtained from the medial
femoral condyle at the same anatomical locations of
both knees of every animal and, within the same proced-
ure a section of the articular capsule adjacent to the pa-
tellar ligament was obtained.
For evaluation, samples were divided in four groups
(Fig. 1): CTRL: healthy non-operated knees of the placebo-
treated animals (n = 8); OA: operated knees of the placebo
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group (n = 8); CTRL +DC: non-operated healthy knees of
the diacerein-treated animals (n = 8); OA +DC: osteoarth-
ritic knees of the diacerein-treated animals (n = 8).
One trephine was decalcified with EDTA (ethylenedi-
aminetetraacetic acid) in acid buffer (Osteodec, Bio-
Optica, Milano, Italy) and, together with the articular
capsule, was paraffin-embedded, sectioned and stained
with haematoxylin-eosin (H-E) and safranin O-fast
green. The synovial membrane slides were stained with
H-E. The second trephine-cylinder was firstly used to
evaluate the architecture of the cartilage and subchon-
dral bone by micro-CT and later it was processed for
undecalcified ground sections according to the method
described by Donath (1985) [20], and stained using the
Lévai-Laczkó method [21].
Microscopic evaluation
The gradation of the samples was performed in the same
way as in a previously published article [19]
The synovial membrane and the decalcified bone and
cartilage core biopsies were evaluated by two independ-
ent observers according to the already published guide-
lines [22, 23]. The gradation of damage to the structures
was as follows: in cartilage, chondrocyte and proteogly-
can pathology from 0 (normal) to 4 (completely affected)
and in tidemark and synovial membrane from 0 (normal)
to 2 (osteoarthritic). In cartilage samples the parameters
evaluated were: the cartilage pathology (cartilage surface
characteristics), chondrocyte pathology (chondrocyte
density and distribution, paying special attention to the
clusters formation), proteoglycan pathology (degree of
staining), tidemark integrity. In synovial membrane slides:
lining cell characteristics (number of superficial cell
layers), hyperplasia (presence or absence and its character-
istics), and the presence or absence of cellular infiltrations.
Quantitative histology was performed using undecalci-
fied sections applying previously published [24] morpho-
logical parameters by a masked examiner using PC-based
image analysis programmes: Cell-sens 1.5 (Olympus Cor-
poration, Japan) and Micro-image 4.0 (Media cybernetics,
Bethesda, MD, USA). Firstly the reference lines were
identified (Fig. 2) and after that, the programme automat-
ically calculated the mean distances between these lines.
The evaluated parameters were [19]: Subchondral
bone cortical thickness (SB.Th), total cartilage thickness
(Cg.Th) and separately non-calcified (nCg.Th) and calci-
fied cartilage thickness (cCg.Th) using the tidemark as
reference (Fig. 2a), cartilage surface undulations (FI)
(Fig. 2b), trabecular subchondral bone area (Tb.A) and
trabecular separation (Tb.Sp). Tb.A and Tb.Sp were mea-
sured in a single subchondral bone region of interest
(ROI) of 4x2mm beginning immediately after the sub-
chondral cortical bone and including the entire width of
the core biopsy except the margins (Fig. 2c). Tb.A was de-
fined as the percentage of trabecular bone in this region
and Tb.Sp as the mean distance between trabeculae.
Micro-computed tomography (micro-CT)
Undecalcified sections were evaluated with a high-
resolution micro-CT (SkyScan 1172, Bruker micro CT
NV, Kontich, Belgium). Two scans were performed for
each sample, one to assess the microstructure of the
subchondral bone and the other to visualise the articular
cartilage using previously published parameters [19]. Im-
ages were reconstructed based on Feldkamp’s convolu-
tion back-projection algorithm [25], and segmented into
binary images. The following direct metric indices were
measured: bone volumetric fraction (BV/TV), trabecular
thickness (Tb.Th) and separation (Tb.Sp), and trabecular
number (Tb.N) [26]. Directly assessed non-metric pa-
rameters were also calculated, including the trabecular
bone pattern factor (Tb.Pf ), which is an inverse measure
of trabecular connectivity [27], the structural model index
(SMI), which estimates the prevalence of rod-like or plate-
like trabeculae [28], and the degree of anisotropy (DA) de-
scribing the orientation of trabeculae [29]. Additionally,
the volumetric bone mineral density (vBMD) was deter-
mined by direct calibration against attenuation coefficients
of two hydroxyapatite phantoms (250 and 750 mg/cm3).
Regarding the cartilage, the average thickness of the non-
calcified cartilage layer (nCg.Th) and its volume (nCg.V)
were 3-D quantified.
Figure 1 Experimental design. Groups of treatment
Permuy et al. BMC Veterinary Research  (2015) 11:143 Page 3 of 11
Statistical analysis
The statistical analysis was performed with SPSS 19 for
Windows (IBM, Armonk, NY, USA). The normality of
the variables was checked by the Shapiro-Wilk test. The
statistical comparison of normal variables was performed
using ANOVA and the Levene’s test was used to assess
the equality of variances. Post-hoc analysis was carried
out using the Tukey’s HSD test for parameters with
equal variances or the Games-Howell test for parameters
with different variances. For non-normal variables, a
statistical comparison was performed using the Kruskal-
Wallis H test and a post-hoc analysis using the Dunn’s
test. The statistical significance level was set at p < 0.05
for all parameters.
Results
No changes in weight or general condition were ob-
served during the experimental protocol. The only out-
standing fact was that animals treated with diacerein
presented urine discoloration; however, no pathological
changes in the kidneys or the rest of the organs were de-
tected in necropsies.
Out of the total of 32 harvested joints, except for one
excluded due to infection, 31 presented an adequate sta-
tus to be histologically analysed.
Quantitative histological results
Mean and standard deviation (SD) of the parameters
quantified on undecalcified samples are shown in Table 1.
The subchondral bone parameters measured in these
calcified slices obtained from CTRL and OA groups were
similar and showed no changes in both treated groups
(CTRL +DC and OA+DC). Regarding the cartilage-
related parameters, non-calcified cartilage thickness
(nCg.Th) showed a significant increase in the OA group
compared to CTRL (p = 0.024) and CTRL + DC (p =
0.009). The OA + DC group (operated knee of the
diacerein-treated animals) showed a decrease of the
nCg.Th with respect to the OA, reaching intermediate
values halfway between CTRL/CTRL + DC and OA but
showing no significant differences compared to none of
them. For the total cartilage thickness (Cg.Th) differ-
ences between CTRL and OA groups are not signifi-
cant, unlike between OA and CTRL + DC groups (p =
0.029). In this case, as well as in the non-calcified cartil-
age, the OA + DC group showed intermediate values
between controls and OA. In relation to the cartilage
surface undulations (FI) there were no statistical differ-
ences between groups, but an almost significant reduc-
tion (p = 0.06) of fibrillation was found between OA
and OA + DC groups (Fig. 3), the latter reaching values
similar to both control groups (CTRL and CTRL + DC).
In the microscopic images of the calcified samples
stained with Levai-Lazckó (Fig. 3 A-D), despite small dif-
ferences in the statistical analysis, several differences be-
tween groups were observed. Cartilage thickness (Cg.Th)
of the OA groups (3B) was thicker than the others, the
OA +DC group (3D) reaching an intermediate thickness
halfway between controls (3A and 3C) and OA. Another
Figure 2 Representative images of the measurements made in undecalcified sections: a cartilage and subcondral bone cortical thickness (nCg.Th;
cCg.Th; Cg.Th = nCg.Th + cCg.Th) SB.Th). b. Surface undulation (FI). c Trabecular subchondral bone measurements in a ROI. Tb.A: % of trabecular
bone in the ROI; Tb.Sp measured on the diagonal of ROI (Tb.Sp = (1/Tb.N)-Tb.Th)
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important finding that may be visualised in the images is
that the OA group had more superficial fibrillation than
the others and the OA + DC surface is similar to those
of the controls. The distribution of chondrocytes in the
cartilage layer, although the cell distribution and cluster
formation was not evaluated in these calcified samples,
was different too, showing more disorganisation in the
OA group (3B) than in the others. Finally, in the image
of the OA group the loss of the part of the calcified car-
tilage (cCg.Th) could be observed, unlike in the others
(3A, 3C, 3D).
Qualitative histological results
The values of microscopic grading for the decalcified
cartilage samples and for the synovial membrane are
shown in Table 2 and Fig. 4.
The parameters that assess changes in non-calcified
cartilage showed no differences between the four groups,
although the results of the severity of cartilage pathology
of the OA +DC group (osteoarthritic knees of the
diacerein-treated animals) are halfway between both
control groups (CTRL and CTRL + DC) and OA, with-
out any statistical differences between them.
Two of the variables determined in the synovial mem-
brane, that is, the features of the lining cells and the
presence of hyperplasia, showed statistical significance
between the OA and CTRL group (p < 0.05), but there
was no presence of inflammatory infiltrates. Between the
two diacerein groups (CTRL + DC and OA +DC) the
only statistical difference is the presence of hyperplasia.
OA +DC shows significant differences compared to OA
in both lining cells characteristics and hyperplasia (Fig. 3)
Table 1 Quantitative histological results
CTRL OA CTRL + DC OA + DC
mean ± std.dev mean ± std.dev mean ± std.dev mean ± std.dev
Subchondral bone
Tb.A (mm2) 46.37 ± 5.41 47.93 ± 7.01 50.69 ± 7.34 45.54 ± 6.83
Tb.Sp (μm) 514.93 ± 235.24 437.79 ± 211.86 534.56 ± 222.56 590.16 ± 272.66
SB.Th (μm) 306.57 ± 76.46 251.60 ± 67.43 264.07 ± 28.36 268.20 ± 47.01
Cartilage
FI (mm) 1.08 ± 0.07 1.22 ± 0.14 1.10 ± 0.16 1.10 ± 0.05
Cg.Th (μm) 493.73 ± 80.73 620.12 ± 114.82c 473.82 ± 87.57b 571.12 ± 96.73
nCg.Th (μm) 338.64 ± 65.03b 465.23 ± 88.92a,c 322.19 ± 82.98b 409.79 ± 82.56
cCg.Th (μm) 155.09 ± 24.94 167.75 ± 43.01 151.69 ± 28.05 161.33 ± 42.09
Comparison of the histological parameters obtained from undecalcified samples between experimental groups. All variables were normally distributed, except FI.
Statistical significance p < 0.05: a vs. CTRL; b vs. OA; c vs. CTRL + DC; d vs. OA + DC
Figure 3 Representative histology images. A-D: Lévai-Laczkó stained undecalcified sections (A CTRL; B OA; C CTRL + DC; D OA + DC), magnification
10x. 1–4: safranin-O/fast green stained decalcified sections (1 CTRL; 2 OA; 3 CTRL + DC; 4 OA +DC), magnification 10x. a-d: synovial membrane sections
stained with H-E (a CTRL; b OA; c CTRL + DC; d OA + DC), magnification 20x
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but not compared to the controls (CTRL and CTRL +
DC). The OA +DC group reaches intermediate values
halfaway between OA and CTRL for the three parame-
ters evaluated in the synovial membrane.
As shown by the results of the histologic qualitative
assessment of the decalcified samples, diacerein treat-
ment resulted in less alteration of the cartilage surface
but not in amelioration of the cellular alterations or in
the loss of proteoglycan staining with respect to the
osteoarthritic samples of the placebo-treated group
(OA). Fig. 3.2 (OA) and 3.4 (OA +DC) shows the chon-
drocyte disorganisation, with cells not arranged in rows,
unlike in the controls (CTRL (3.1) and CTRL + DC
(3.3)), and the evident formation of clusters, as well as
the loss of the red stain, especially in the superficial
layers of the cartilage.
In the synovial membrane of both control groups
(Fig. 3.a and 3.c) the lining surface was thin, with one or
two layers of cells, the surface was smooth, with no pres-
ence of short villi or finger-like hyperplasia, or of inflam-
matory infiltrations. The OA group (Fig. 3.b) was in the
opposite situation, with a thick lining surface, profuse
hyperplasia, presence of diffuse inflammatory infiltration
and a deposition of fibrous tissue below the intima tis-
sue. Finally, in the OA + DC group (Fig. 3.d), the number
of superficial layers of cells tend to approach to the
controls, as well as hyperplasia, these samples exhibiting
less fibrous subintima tissue than the OA group.
Micro-CT results
The mean and SD values for the micro-CT parameters
are shown in Table 3.
Comparing micro-CT data from the OA group versus
the CTRL group, there were no differences in any of the
microstructural parameters referring to the subchondral
bone or volumetric bone mineral density (vBMD). In
contrast, both the thickness of cartilage (nCg.Th) and its
volume (nCg.V) are significantly increased in the OA
group with respect to CTRL (p = 0.003 and 0.018, re-
spectively) and to CTRL + DC (p < 0.001 and p = 0.003)
(Fig. 5).
For the OA +DC group, the subchondral bone mea-
surements show differences only with OA regarding the
degree of anisotropy (p = 0.004), the rest of the results
being similar to those obtained from the other groups.
Nonetheless for cartilage parameters, OA + DC showed
nCg.V and nCg.Th values close to those of the healthy
control group (CTRL); thus, the value of nCg.Th in the
OA +DC group presents statistically significant differ-
ences compared to OA (p = 0.041), whereas nCg.V is al-
most significant (p = 0.053) (Fig. 5).
Table 2 Qualitative histological results
CTRL OA CTRL + DC OA + DC
median (25, 75) median (25, 75) median (25, 75) median (25, 75)
μ ± std.dev μ ± std.dev μ ± std.dev μ ± std.dev
Microscopic grading of cartilage alterations
Severity of cartilage pathology 0 (0, 0.75) 1 (0.25, 1.75) 0 (0, 0.5) 0 (0, 1)
0.29 ± 0.49 1 ± 0.82 0.25 ± 0.46 0.5 ± 0.76
Severity of chondrocyte pathology 0 (0, 1) 1 (0.25, 2.5) 1 (0, 1) 1 (1, 3)
0.57 ± 0.79 1.21 ± 1.15 0.56 ± 0.5 1.81 ± 1.19
Severity of proteoglycan pathology 0 (0, 0) 1 (0, 2) 0 (0, 3) 1.5 (0, 3)
0.33 ± 0.82 1.29 ± 1.5 1.25 ± 1.83 1.56 ± 1.68
Tidemark integrity 1 (0.5, 2) 0 (0, 2) 1 (1, 1) 0.5 (0, 2)
1.13 ± 0.83 0.67 ± 1.03 1 ± 0.53 0.88 ± 0.99
Microscopic grading of synovial changes
Lining cells characteristics 0 (0, 0)b,c,d 1 (1, 1)a,c,d 0 (0, 1)a,b 0 (0, 0.75)a,b
0 ± 0 1 ± 0.63 0.4 ± 0.55 0.29 ± 0.49
Presence of hyperplasia 0 (0, 0)b,c,d 1 (1, 2)a,c,d 0 (0, 0.25)a,b,d 1 (0.25, 1)a,b,c
0.13 ± 0.35 1.17 ± 0.75 0.2 ± 0.45 0.86 ± 0.69
Cell infiltration characteristics 0 (0, 0) 1 (0, 1) 0 (0, 1) 0 (0, 0.75)
0 ± 0 0.67 ± 0.52 0.4 ± 0.55 0.29 ± 0.49
Comparison between experimental groups with different scores for microscopic grading of cartilage and synovial alterations, obtained from decalcified samples.
All parameters showed a non-normal distribution. Statistical significance p < 0.05: a vs. CTRL; b vs. OA; c vs. CTRL + DC; d vs. OA + DC
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Figure 4 Box plot comparing the scores obtained by the different experimental groups for qualitative microscopic grading of cartilage and
synovial alterations (decalcified samples). Outside values were defined as the values that were smaller than the lower quartile minus 1.5 times
the interquartile range or larger than the upper quartile plus 1.5 times the interquartile range (inner fences). CTRL: healthy + placebo; OA:
osteoarthritis + placebo; CTRL + DC: healthy + diacerein; OA + DC: osteoarthritis + diacerein. All parameters showed a non-normal distribution.
Statistical significance p < 0.05: a vs. CTRL; b vs. OA; c vs. CTRL + DC; d vs. OA + DC
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In the healthy group treated with diacerein (CTRL +
DC), the drug showed an anabolic effect on the sub-
chondral bone structure, with an increase in bone vol-
ume fraction (BV/TV) versus CTRL (p = 0.029), besides
a decrease in trabecular separation and degree of anisotropy
(p = 0.032 and 0.001 respectively). The microstructural pa-
rameters measured in cartilage showed no difference be-
tween both control groups.
Discussion
Diacerein has been subject of study regarding its use in
the treatment of human OA for some time now. Animal
models have been widely used to study the efficacy of
therapies in order to improve, fight or prevent OA.
Surgically-induced OA models, resulting in joint in-
stability, produce a gradual progression of the joint de-
generation and mimic the pathogenesis and pathology of
the human traumatic OA [30, 31]. Since the first model
carried out by Paatsama (1952) [32], many studies have
surgically induced OA using meniscectomy and/or tran-
section of the collateral and cruciate ligaments in differ-
ent animal species [33]. Partial medial meniscectomy in
rabbits results in mild to moderate changes in the joint,
resembling those in humans, thus it has been extensively
used for testing potential chondroprotective agents [34].
Our animal model was a combination of meniscectomy
and ligament transection to avoid the great capacity of
rabbits to heal the transected meniscus with fibrous tis-
sue and, similarly to the results obtained by other au-
thors, the results in the present study have shown that
this model produced degenerative changes with respect
to the healthy contralateral joint [30]. Although the ani-
mals were sacrificed at 11 weeks post-surgery, OA
seemed to have begun developing, as proven by the
swelling of the cartilage. The increase in volume and
thickness of cartilage of the OA samples is due to a
swelling phenomenon characteristic to the early stages
of the disease. Several studies on animals of early OA
Table 3 Micro-CT results
CTRL OA CTRL + DC OA + DC
mean ± std.dev mean ± std.dev mean ± std.dev mean ± std.dev
Subchondral bone microstructure
BV/TV (%) 48.46 ± 7.74c 49.37 ± 4.38 56.34 ± 2.96a 51.92 ± 4.99
Tb.Th (μm) 265.21 ± 32.62 288.75 ± 60.43 283.20 ± 34.22 281.18 ± 56.18
Tb.Sp (μm) 467.24 ± 122.46c 423.12 ± 66.21 354.74 ± 36.25a 433.27 ± 54.03
Tb.N (mm−1) 1.83 ± 0.20 1.76 ± 0.29 2.01 ± 0.23 1.89 ± 0.30
Tb.Pf (mm−1) −3.27 ± 1.49 −3.24 ± 0.51 −4.16 ± 1.54 −4.01 ± 1.15
SMI −0.66 ± 0.47 −0.72 ± 0.39 −1.07 ± 0.48 −0.96 ± 0.60
DA 0.71 ± 0.06c,d 0.69 ± 0.06c,d 0.57 ± 0.09a,b 0.57 ± 0.06a,b
Volumetric subchondral bone mineral density
vBMD (mg/cm3) 505.90 ± 98.53 512.78 ± 52.52c 608.36 ± 24.43b 548.69 ± 58.95
Cartilage morphology
nCg.Th (μm) 309.06 ± 62.99b 494.80 ± 169.59a,c,d 269.01 ± 39.93b 359.75 ± 48.62b
nCg.V (mm3) 3.37 ± 0.78b 5.69 ± 2.72a,c 2.81 ± 0.52b 3.71 ± 0.50
Mean values ± standard deviation of the micro-CT parameters obtained for all experimental groups. All variables showed a normal distribution, and only vBMD
showed no homogeneity of variances. Statistical significance p < 0.05: a vs. CTRL; b vs. OA; c vs. CTRL + DC; d vs. OA + DC
Figure 5 Micro-CT 3D models of a representative sample of each experimental group. Cartilage swelling characteristic of the first stages of OA
can be clearly appreciated in OA samples, whereas diacerein-treated samples recover normal cartilage morphology like CTRL
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with magnetic resonance imaging and histomorphome-
try identified an initial phase of cartilage hypertrophy
prior to its degeneration and loss [35, 36]. The explan-
ation has not been found yet, and it is not known
whether it is the tissue expression to an inflammatory
and repair phenomenon or if it represents a permanent
damage of the joint tissue.
Special attention should be paid to the methodology
used in this study. Samples of subchondral bone and ar-
ticular cartilage were analysed using different quantita-
tive and qualitative microscopic methods and micro-CT.
Histologic assessment of OA is currently considered as
the gold-standard for determining the presence, extent
and severity of the disease using Mankin [37] or modi-
fied Mankin scoring systems, but recently the histomor-
phometry using computer analysis systems [24] has been
introduced in OA studies with a greater degree of ob-
jectivity and reproducibility compared to previous quali-
tative studies.
Micro-CT has become in recent years the gold-
standard for three-dimensional analysis of bone micro-
structure and its objectivity and reproducibility was
comparable to histomorphometry. Although normally
when the cartilage structure was quantified using
micro-CT, the process involved complex staining tech-
niques with radiopaque agents [38–40], in the present
study the scan conditions have been adjusted to achieve
a correct cartilage visualisation without contrast agents
and it was enough to be able to quantify its
morphology.
Our results revealed the potential anti-inflammatory
effects of diacerein on osteoarthritis in two different
ways: an improvement in the synovial membrane and a
reduction in the thickness of the non-calcified cartilage.
Previous studies revealed the beneficial effect of this
drug not only for cartilage protection, but also for syno-
vitis and reduction in bone erosion in a mice model of
inflammatory arthritis [41]. The mechanisms of the anti-
inflammatory effect of diacerein have not yet been
completely clarified but Tamura et al. (2002) [42] dem-
onstrated, using inflammatory animal models, a different
spectrum of anti-inflammatory activity of diacerein than
those of NSAIDs, which may be due to the inhibition of
IL-1 and the production of reactive oxygen species [42,
43]. The histologic evaluation of the synovial membrane
in the OA group revealed moderate to severe inflamma-
tory changes with thickening of the lining cell layer,
hyperplasia and infiltration with inflammatory cells. In
the diacerein-treated group (OA + DC) these changes
are milder than in the OA group, although, as in a ca-
nine cruciate-deficiency model [12] the results are not
statistically significant, as the animals of this OA + DC
group obtained values halfway between healthy and
osteoarthritic ones. The same results were observed in
the cartilage, where a reduction of the thickness is ob-
served in treated animals with respect to the OA group.
In the paraffin-embedded samples there were no dif-
ferences between groups (although the cartilage path-
ology is almost significant). A possible explanation could
be the substantial variability due to the use of a qualita-
tive subjective scoring system for their evaluation; an-
other explanation (comparing these results with the
calcified samples) could be that due to decalcification
the integrity of the samples (chiefly bone and calcified
cartilage) may have been altered [24]. However, in decal-
cified samples, the results for the OA + DC group were
closer to normality than those obtained for the OA
group.
In the samples evaluated by a histomorphometric
quantitative methodology, results showed improvement
in the diacerein-treated group compared to the one
treated with placebo, although differences were not sig-
nificant. In cartilage parameters there were statistical dif-
ferences in Cg.Th and nCg.Th between the OA group
and the CTRL + DC group and for the latter also with
the CTRL group. There were no differences between
OA and OA +DC, but nor between OA +DC and
CTRL + DC and the tendency of values was to approxi-
mate joint values to normal. Regarding FI -an important
parameter because it makes a clear distinction between
ill and healthy animals [44]- there were no statistical dif-
ferences between groups, but there is a tendency of ap-
proximating values of OA +DC to those of controls.
The results obtained from the undecalcified samples
were better than those from the decalcified ones because
of a better conservation of the tissue structure and be-
cause the computer evaluation has a greater degree of
objectivity, accuracy and reproducibility, as well as the
micro-CT [24], with comparable results between both.
In our study, the subchondral bone showed no statistical
differences, so further studies may be needed in this
regard.
Micro-CT data have shown an anabolic effect of dia-
cerein on subchondral trabecular microstructure in both
healthy and osteoarthritic samples (though less pro-
nounced in the latter). At the same time, the treatment
has been able to stop the swelling of cartilage in OA
samples, recovering nCg.Th and nCg.V values very close
to the CTRL group.
The results of the present animal study conducted in
rabbits suggest the possible efficacy of diacerein to slow
the progression of the disease in an early model of OA,
as shown in previous studies in vitro [45], in different
animal models [12, 42, 45, 46] and in clinical trials [7,
16, 47]; although the comparison of different studies is
difficult because of their high degree of heterogeneity
(different models conducted in different animal species
and humans, different time schedule and others). To
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complete this study and correctly evaluate the obtained
results, it may be necessary to evaluate the effects of dia-
cerein treatment in the same animal model with a more
advanced OA.
Conclusions
Oral diacerein as OA treatment has been able to reduce
cartilage swelling, surface alterations and the inflamma-
tion of the synovial membrane in the early stages of OA
in a rabbit surgical model. Regarding the subchondral
bone, diacerein has shown in healthy bone, but not in
the osteoarthritic one, the ability to increase bone vol-
ume and mineral density, indicating a surprising effect
of this drug on the bone structure, whose results have
not been published up to now.
The study also demonstrates the validity of the animal
model, and that micro-CT could be a valid technique to
detect morphological changes in articular cartilage with
comparable results to histomorphometry.
Further studies on long-term OA animal models and
well-conducted clinical trials may be required to confirm
or exclude the efficacy of diacerein in the treatment of
knee OA.
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